头颈部鳞癌术后辅助放化疗的研究现状  

Adjuvant chemoradiotherapy for postoperative head and neck squamous cell carcinoma

作　　者：陆雪官[1] 胡超苏[1] LU Xueguan;HU Chaosu(Department of Radiation Oncology, Fudan University Shanghai Caner Center;Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China)

机构地区：[1]复旦大学附属肿瘤医院放疗科,复旦大学上海医学院肿瘤学系,上海200032

出　　处：《中国癌症杂志》2017年第6期463-470,共8页China Oncology

摘　　要：临床研究显示,术后放化疗能够提高头颈部鳞癌术后高危患者的治疗疗效。放疗实施时需根据原发肿瘤部位、临床分期、术后病理和术后影像学评估情况来确定照射靶区和剂量。目前临床上推荐放疗同步应用单药顺铂方案已经达成共识,而放疗同步联合其他化疗药物和(或)表皮生长因子受体(epidermal growth factor receptor,EGFR)单抗的疗效则仍不确定。人乳头状瘤病毒(human papillomavirus,HPV)阳性口咽癌具有独特的生物学特性,其术后放化疗适应证和辅助放化疗的治疗模式至今仍不明确,值得深入研究。Emerging clinical evidence revealed that postoperative adjuvant chemoradiotherapy(CRT)could improve the clinical outcome for resected head and neck squamous cell carcinoma in high-risk patients.The irradiation targets and doses should be determined by the primary tumor site,clinical stage,pathology reports,and the evaluation of postoperative imaging.Adjuvant concurrent CRT with cisplatin is the current standard treatment for high-risk postoperative head and neck squamous cell carcinoma patients.However,the effect of concurrent CRT with otherchemotherapeutic agents and(or)epidermal growth factor receptor(EGFR)monoclonal antibody in these patients is inconclusive.Human papillomavirus(HPV)-positive oropharyngeal cancer has the unique biological characteristics,and the indications and treatment models of postoperative adjuvant CRT for these patients are still unclear.Further study is needed.

关 键 词：头颈部肿瘤 鳞癌 放疗 化疗 分子靶向治疗 

分 类 号：R739.91[医药卫生—肿瘤]